Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
Bio-Techne Corporation (NASDAQ: TECH) announced an expanded collaboration with Catamaran Bio to enhance cell engineering and manufacturing technologies for CAR-NK cell therapies. The new agreement includes a worldwide license for the TcBuster™ transposon system, which allows for efficient gene editing, integrated into Catamaran's TAILWIND™ Platform. This partnership aims to advance scalable, robust manufacturing processes for allogeneic CAR-NK therapies, targeting cancer treatments, especially solid tumors. Bio-Techne generated approximately $739 million in net sales in fiscal 2020.
Bio-Techne Corporation (NASDAQ: TECH) has partnered with Autolomous to implement the AutoloMATETM electronic batch record system at its GMP cellular manufacturing center. This initiative aims to enhance process control in cell-based therapies, ensuring higher quality standards for patient products. Bio-Techne will provide therapeutic companies with state-of-the-art electronic records and integrate further technologies within their platforms. This marks Autolomous's first deployment in the USA, showcasing the flexibility of their solutions for various cell and gene therapy workflows.
Bio-Techne Corporation (NASDAQ: TECH) announced its membership in the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium. This initiative, comprising over 20 pharmaceutical and technology organizations, aims to enhance process analytics in the cell and gene therapy sector. The collaboration focuses on developing specific analytical technologies to improve manufacturing processes, which could lead to better batch yields and lower costs. CEO Chuck Kummeth expressed optimism about sharing knowledge to advance the industry and enhance patient outcomes through innovative therapies.
Kantaro Biosciences, a joint venture involving RenalytixAI (RNLX) and the Mount Sinai Health System, has received Health Canada Authorization for its COVID-SeroKlir semi-quantitative antibody test kit. This kit can detect the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity. Importantly, it is available for immediate use in Canadian laboratories without proprietary equipment. The test has already been deployed over 127,000 times on diverse populations, offering significant potential for guiding public health policies as Canada reopens.
Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. EDT. The presentation will be available through a live webcast on the company's Investor Relations website. Bio-Techne specializes in developing high-quality purified proteins and reagent solutions, generating approximately $739 million in net sales for FY 2020. With about 2,600 employees globally, the company plays a critical role in biomedical research and clinical diagnostics.
Bio-Techne Corporation (NASDAQ: TECH) has announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders using its Ella platform. This platform offers high-quality, automated immunoassays with results delivered in 90 minutes using only 25 µL of sample. Under the collaboration, Ella instruments will be provided for clinical trials in India, aiming for regulatory approval as a diagnostic device. Executives highlighted Ella's potential to enhance diagnostics in ophthalmology.
Bio-Techne Corporation (NASDAQ:TECH) announced the successful results of the AmplideX® PCR/CE SMA Plus Kit from a multisite evaluation study. Published in The Journal of Molecular Diagnostics, the kit showed 98.6% accuracy for SMN1 and 97.1% for SMN2 in diagnosing spinal muscular atrophy (SMA), a condition affecting 1 in 6,000 births. The kit facilitates carrier screening and diagnosis in a streamlined manner, critical for timely treatment. The study involved 468 clinical samples across several international laboratories demonstrating high concordance with established diagnostic methods.
Bio-Techne Corporation (NASDAQ: TECH) has announced a quarterly dividend of $0.32 per share for the period ending March 31, 2021. This dividend will be paid on May 28, 2021 to shareholders recorded by May 17, 2021. The company, a global leader in life sciences, reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. The Board will continue to evaluate future dividends on a quarterly basis.
Bio-Techne Corporation (NASDAQ:TECH) reported strong financial results for Q3 FY2021, with organic revenue growth of 22% to $243.6 million. GAAP EPS increased to $1.12, up from $0.92 last year, while adjusted EPS rose to $1.79 from $1.39. The company achieved a remarkable adjusted operating margin of 40.1%, reflecting effective cost management and higher demand across its segments. Notably, Protein Sciences experienced organic growth of 24%, while Diagnostics and Genomics grew by 17%. Bio-Techne also enhanced its Diagnostics segment through the acquisition of Asuragen.
